These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33050484)

  • 21. Molecular Approaches Target to Immunotherapy for HPV-Associated Cancers.
    Zhang L; Zhou F; Zhao KN
    Curr Cancer Drug Targets; 2017; 17(6):512-521. PubMed ID: 27993116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [The first vaccine against cancer: the human papillomavirus vaccine].
    Bősze P
    Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
    Arbyn M; Dillner J
    J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer.
    Hammer A; Mejlgaard E; Gravitt P; Høgdall E; Christiansen P; Steiniche T; Blaakaer J
    Acta Obstet Gynecol Scand; 2015 Nov; 94(11):1262-8. PubMed ID: 26300424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HPV: Molecular pathways and targets.
    Gupta S; Kumar P; Das BC
    Curr Probl Cancer; 2018; 42(2):161-174. PubMed ID: 29706467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
    Hantz S; Alain S; Denis F
    Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
    Riethmuller D; Jacquard AC; Lacau St Guily J; Aubin F; Carcopino X; Pradat P; Dahlab A; Prétet JL
    BMC Public Health; 2015 May; 15():453. PubMed ID: 25934423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
    Wick DA; Webb JR
    Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer.
    Franceschi S
    Recent Results Cancer Res; 2005; 166():277-97. PubMed ID: 15648196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
    Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
    Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human papillomavirus disease and vaccines.
    Hutchinson DJ; Klein KC
    Am J Health Syst Pharm; 2008 Nov; 65(22):2105-12. PubMed ID: 18997137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists.
    McIntosh J; Sturpe DA; Khanna N
    J Am Pharm Assoc (2003); 2008; 48(1):e1-13; quiz e14-7. PubMed ID: 18192123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human papillomavirus, cervical cancer, and the vaccines.
    Tovar JM; Bazaldua OV; Vargas L; Reile E
    Postgrad Med; 2008 Jul; 120(2):79-84. PubMed ID: 18654072
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Human papillomavirus vaccines: current issues & future.
    Kawana K; Yasugi T; Taketani Y
    Indian J Med Res; 2009 Sep; 130(3):341-7. PubMed ID: 19901444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine.
    Ährlund-Richter A; Cheng L; Hu YOO; Svensson M; Pennhag AAL; Ursu RG; Haeggblom L; Grün N; Ramqvist T; Engstrand L; Dalianis T; Du J
    Front Cell Infect Microbiol; 2019; 9():59. PubMed ID: 30949454
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
    Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
    Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overview of the benefits and potential issues of the nonavalent HPV vaccine.
    Mariani L; Preti M; Cristoforoni P; Stigliano CM; Perino A
    Int J Gynaecol Obstet; 2017 Mar; 136(3):258-265. PubMed ID: 28087890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HPV Vaccination: The Position Paper of the Italian Society of Colposcopy and Cervico-Vaginal Pathology (SICPCV).
    Ciavattini A; Giannella L; De Vincenzo R; Di Giuseppe J; Papiccio M; Lukic A; Delli Carpini G; Perino A; Frega A; Sopracordevole F; Barbero M; Gultekin M
    Vaccines (Basel); 2020 Jul; 8(3):. PubMed ID: 32630772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines.
    Van Damme P; Bonanni P; Bosch FX; Joura E; Kjaer SK; Meijer CJ; Petry KU; Soubeyrand B; Verstraeten T; Stanley M
    Vaccine; 2016 Feb; 34(6):757-61. PubMed ID: 26772631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.